What is the current Price Target for the Imara Inc stock?

The average Imara Inc target price is $37.17. This is 49.38% higher than the current stock price. The highest price target is 60.77%, the lowest is 32.64%. 6 Analysts have issued a price target Imara Inc 2025 .

How high will the Imara Inc stock rise?

No reliable answer can be given as to how high the Imara Inc stock will rise. The performance of stocks, including the Imara Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Imara Inc stock today?

The performance of Imara Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Imara Inc stock fall?

The decline in Imara Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Imara Inc Forecast, price target & analysts

$24.88

1.39%

Nasdaq, Mon, Nov 25 2024

ISIN

US45249V1070

Symbol

IMRA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

Imara Inc Target price 2024 - Analyst rating & recommendation

Imara Inc Classifications & Recommendation:

Buy

100%

Imara Inc Price Target

Target Price	$37.17
Price	$24.88
Potential	49.38% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target Imara Inc 2025 . The average Imara Inc target price is $37.17. This is 49.38% register free of charge higher than the current stock price. The highest price target is $40.00 60.77% register free of charge , the lowest is $33.00 32.64% register free of charge .
	A rating was issued by 7 analysts: 7 Analysts recommend Imara Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Imara Inc stock has an average upside potential 2025 of 49.38% register free of charge . Most analysts recommend the Imara Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-2.01	-1.94
	83.32%	3.48%
P/E		negative

2 Analysts have issued a Imara Inc forecast for earnings per share. The average Imara Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-2.01	83.32%
2024	$-1.94 3.48% Unlock
2025	$-2.03 4.64% Unlock
2026	$-2.15 5.91% Unlock
2027	$-2.29 6.51% Unlock
2028	$-2.58 12.66% Unlock

Current	-13.05	125.32%
2024	-12.82 1.76% Unlock
2025	-12.29 4.13% Unlock
2026	-11.57 5.86% Unlock
2027	-10.86 6.14% Unlock
2028	-9.64 11.23% Unlock

Imara Inc...

Discover more stocks with a high price target

Valneva 284.61%

CureVac N.V. 145.33%

Moderna 70.75%

Bavarian Nordic 61.25%

Nel ASA 44.74%

Aixtron 43.84%

Volkswagen VZ 41.85%

Alibaba Group Holding Ltd 40.45%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now